Muscagen, founded in 2000, is a computation based, rational drug discovery company. It uses analysis of 3D protein structures, a proprietary model of receptor action, and state-of-the-art software, to design molecules which interact with receptors on the surface of human cells in specific ways.
The objective is to produce candidate drugs for valuable target markets from limited numbers of these molecules. Its approach is potentially cost-effective, efficient, reduces animal testing, and avoids likely side effects. The company’s core activity is the design and structural optimisation of potent molecules that show highly selective receptor action. The synthesis and testing of these molecules are not core activities of Muscagen, and will be done in close collaboration with industry partners.